Three months after retrieving rights to the lymphoma drug EPZ-6438 from Eisai in a $110 million deal, Epizyme has posted a positive glimpse at the drug’s efficacy in a small, early-stage trial. And the news swiftly stoked the Cambridge, MA-based biotech’s share price, which soared by 30% as investors pondered the possibilities.

…read more

Source: Glimpse of promising lymphoma responses spurs a sharp spike in Epizyme shares


0 No comments